FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 325:551-555 August 22, 1991 Number 8 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

BACKGROUND AND METHODS. Most strains of herpes simplex virus that are resistant to acyclovir are susceptible in vitro to both foscarnet and vidarabine. We conducted a randomized trial to compare foscarnet with vidarabine in 14 patients with the acquired immunodeficiency syndrome (AIDS) and mucocutaneous herpetic lesions that had been unresponsive to intravenous therapy with acyclovir for a minimum of 10 days. The patients were randomly assigned to receive either foscarnet (40 mg per kilogram of body weight intravenously every 8 hours) or vidarabine (15 mg per kilogram per day intravenously) for 10 to 42 days. In the isolates of herpes simplex virus we documented in vitro resistance to acyclovir and susceptibility to foscarnet and vidarabine. RESULTS. The lesions in all eight patients assigned to foscarnet healed completely after 10 to 24 days of therapy. In contrast, vidarabine was discontinued because of failure in all six patients assigned to receive it. The time to complete healing (P = 0.01), time to 50 percent reductions in the size of the lesions (P = 0.01) and the pain score (P = 0.004), and time to the end of viral shedding (P = 0.006) were all significantly shorter in the patients assigned to foscarnet. Three patients had new neurologic abnormalities while receiving vidarabine. No patient discontinued foscarnet because of toxicity. Although initial recurrences of herpes simplex infection after the index lesion had healed tended to be susceptible to acyclovir, acyclovir-resistant infection eventually recurred in every healed patient, a median of 42.5 days (range, 14 to 191) after foscarnet was discontinued. CONCLUSIONS. For the treatment of acyclovir-resistant herpes simplex infection in patients with AIDS, foscarnet has superior efficacy and less frequent serious toxicity than vidarabine. Once the treatment is stopped, however; there is a high frequency of relapse.

Source Information

Department of Medicine, University of California, San Francisco.

This article has been cited by other articles:

• Wang, K., Mahalingam, G., Hoover, S. E., Mont, E. K., Holland, S. M., Cohen, J. I., Straus, S. E. (2007). Diverse Herpes Simplex Virus Type 1 Thymidine Kinase Mutants in Individual Human Neurons and Ganglia. J. Virol. 81: 6817-6826 [Abstract] [Full Text]  
• Bestman-Smith, J., Boivin, G. (2003). Drug Resistance Patterns of Recombinant Herpes Simplex Virus DNA Polymerase Mutants Generated with a Set of Overlapping Cosmids and Plasmids. J. Virol. 77: 7820-7829 [Abstract] [Full Text]  
• Duan, J., Liuzzi, M., Paris, W., Liard, F., Browne, A., Dansereau, N., Simoneau, B., Faucher, A.-M., Cordingley, M. G. (2003). Oral Bioavailability and In Vivo Efficacy of the Helicase-Primase Inhibitor BILS 45 BS against Acyclovir-Resistant Herpes Simplex Virus Type 1. Antimicrob. Agents Chemother. 47: 1798-1804 [Abstract] [Full Text]  
• Reyes, M., Shaik, N. S., Graber, J. M., Nisenbaum, R., Wetherall, N. T., Fukuda, K., Reeves, W. C., for the Task Force on Herpes Simplex Virus Resista, (2003). Acyclovir-Resistant Genital Herpes Among Persons Attending Sexually Transmitted Disease and Human Immunodeficiency Virus Clinics. Arch Intern Med 163: 76-80 [Abstract] [Full Text]  
• Bacon, T. H., Levin, M. J., Leary, J. J., Sarisky, R. T., Sutton, D. (2003). Herpes Simplex Virus Resistance to Acyclovir and Penciclovir after Two Decades of Antiviral Therapy. Clin. Microbiol. Rev. 16: 114-128 [Abstract] [Full Text]  
• Chaudhuri, A, Kennedy, P G E (2002). Diagnosis and treatment of viral encephalitis. Postgrad. Med. J. 78: 575-583 [Abstract] [Full Text]  
• Hammond, J. L., Koontz, D. L., Bazmi, H. Z., Beadle, J. R., Hostetler, S. E., Kini, G. D., Aldern, K. A., Richman, D. D., Hostetler, K. Y., Mellors, J. W. (2001). Alkylglycerol Prodrugs of Phosphonoformate Are Potent In Vitro Inhibitors of Nucleoside-Resistant Human Immunodeficiency Virus Type 1 and Select for Resistance Mutations That Suppress Zidovudine Resistance. Antimicrob. Agents Chemother. 45: 1621-1628 [Abstract] [Full Text]  
• Bestman-Smith, J., Schmit, I., Papadopoulou, B., Boivin, G. (2001). Highly Reliable Heterologous System for Evaluating Resistance of Clinical Herpes Simplex Virus Isolates to Nucleoside Analogues. J. Virol. 75: 3105-3110 [Abstract] [Full Text]  
• Drake, S., Taylor, S., Brown, D., Pillay, D. (2000). Regular review: Improving the care of patients with genital herpes. BMJ 321: 619-623 [Full Text]  
• Huycke, M. M., Naguib, M. T., Stroemmel, M. M., Blick, K., Monti, K., Martin-Munley, S., Kaufman, C. (2000). A Double-Blind Placebo-Controlled Crossover Trial of Intravenous Magnesium Sulfate for Foscarnet-Induced Ionized Hypocalcemia and Hypomagnesemia in Patients with AIDS and Cytomegalovirus Infection. Antimicrob. Agents Chemother. 44: 2143-2148 [Abstract] [Full Text]  
• (2000). Management of herpes virus infections following transplantation. J Antimicrob Chemother 45: 729-748 [Full Text]  
• Andrei, G., Snoeck, R., De Clercq, E., Esnouf, R., Fiten, P., Opdenakker, G. (2000). Resistance of herpes simplex virus type 1 against different phosphonylmethoxyalkyl derivatives of purines and pyrimidines due to specific mutations in the viral DNA polymerase gene. J. Gen. Virol. 81: 639-648 [Abstract] [Full Text]  
• Piret, J., Désormeaux, A., Gourde, P., Juhász, J., Bergeron, M. G. (2000). Efficacies of Topical Formulations of Foscarnet and Acyclovir and of 5-Percent Acyclovir Ointment (Zovirax) in a Murine Model of Cutaneous Herpes Simplex Virus Type 1 Infection. Antimicrob. Agents Chemother. 44: 30-38 [Abstract] [Full Text]  
• Balfour, H. H. (1999). Antiviral Drugs. NEJM 340: 1255-1268 [Full Text]  
• Tachedjian, G., French, M., Mills, J. (1998). Coresistance to Zidovudine and Foscarnet Is Associated with Multiple Mutations in the Human Immunodeficiency Virus Type 1 Reverse Transcriptase. Antimicrob. Agents Chemother. 42: 3038-3043 [Abstract] [Full Text]  
• Pillay, D., Zambon, M. (1998). Antiviral drug resistance. BMJ 317: 660-662 [Full Text]  
• Lateef, F., Don, P. C., Kaufmann, M., White, S. M., Weinberg, J. M. (1998). Treatment of Acyclovir-Resistant, Foscarnet-Unresponsive HSV Infection With Topical Cidofovir in a Child With AIDS. Arch Dermatol 134: 1169-1170 [Full Text]  
• Borrego, L., Castro, I., Frances, A., Gimeno, C., Soler, E. (1996). Treatment of Acyclovir-Resistant Perianal Herpetic Ulceration With Intramuscular Interferon Alfa. Arch Dermatol 132: 1157-1158 [Abstract]  
• Pillay, D., Geddes, A. M (1996). Antiviral drug resistance. BMJ 313: 503-504 [Full Text]  
• Cunningham, E. T. Jr, Short, G. A., Irvine, A. R., Duker, J. S., Margolis, T. P. (1996). Acquired Immunodeficiency Syndrome--Associated Herpes Simplex Virus Retinitis: Clinical Description and Use of a Polymerase Chain Reaction--Based Assay as a Diagnostic Tool. Arch Ophthalmol 114: 834-840 [Abstract]  
• Rossi, S., Whitfeld, M., Berger, T. G. (1995). The Treatment of Acyclovir-Resistant Herpes Zoster With Trifluorothymidine and Interferon Alfa. Arch Dermatol 131: 24-26 [Abstract]  
• Kost, R. G., Hill, E. L., Tigges, M., Straus, S. E. (1993). Recurrent Acyclovir-Resistant Genital Herpes in an Immunocompetent Patient. NEJM 329: 1777-1782 [Full Text]  
• Vitale, V. J., Saiman, L., Haddad, J. Jr (1993). Herpes Laryngitis and Tracheitis Causing Respiratory Distress in a Neonate. Arch Otolaryngol Head Neck Surg 119: 239-240 [Abstract]  
• Stoeckle, M. Y., Douglas, R. G. Jr (1992). Infectious Diseases. JAMA 268: 366-368 [Abstract]  
• Paar, D., Masur, H. (1992). Advances in the Management of Major Opportunistic Infections in Patients with Human Immunodeficiency Virus Infection. Journal of Pharmacy Practice 5: 131-142